The HRR Track Test analyses a set of genes involved in DNA repair. It uses Next-Generation Sequencing (NGS) to identify mutations in HRR genes that may lead to cancer growth. The test also helps predict a patient’s response to targeted therapies such as PARP inhibitors, which are effective in treating HRR-deficient cancers.
HRR Track Test
What is HRR Track Test?
The HRR Track Test is an advanced genetic screening tool designed to detect mutations in Homologous Recombination Repair (HRR) genes, which play a crucial role in DNA damage repair. Deficiencies in HRR pathways are linked to various cancers, including ovarian, breast, prostate, and pancreatic cancers, making them key biomarkers for treatment decisions. This test utilises Next-Generation Sequencing (NGS) to analyse a panel of HRR-related genes, helping clinicians assess a patient’s eligibility for PARP inhibitor therapies and other targeted treatments. By identifying HRR mutations, the HRR Track Test enables personalised cancer management and guides therapeutic strategies for improved patient outcomes.
HRR Pathway Gene List
| Gene List | Gene List | Gene List |
|---|---|---|
| ATM | BRCA2 | CHEK1 |
| PALB2 | RAD51C | BARD1 |
| BRIP1 | CHEK2 | PPP2R2A |
| RAD51D | BRCA1 | CDK12 |
| FANCL | RAD51B | RAD54L |
Clinical Applications of HRR Track Test
- Predicts PARP inhibitor and platinum sensitivity.
- Refines risk and response prediction.
- Enables tailored and personalised treatment.
- Determines eligibility for clinical trails.
- Detects acquired mutations linked to treatment failure.
Specification
- Indications: Breast Cancer, Ovarian Cancer, Pancreatic Cancer and Prostate Cancer.
- Methodology: Next-Generation Sequencing (NGS).
- Sample Type: Tissue Biopsy: FFPE Tissue blocks (Minimum of 20% tumor content; Sample should be accompanied by an HPE Report and an IHC report) Liquid Biopsy: 2* 10ml of Peripheral blood in Streck tube Germline: Bone Marrow Aspirate / Peripheral Blood in EDTA.
- Accuracy: Average Depth of sequencing (Pre UMI): ≥20,000X I Average Depth of sequencing (Post UMI): ≥1000X.
- Coverage: SNVs & InDels. Detects both somatic and germline variants. Complete coding regions and splice site boundaries (+ / -10 bp) are covered.
HRR Track Tests Offered by MedGenome
Homologous Recombination Repair (HRR) pathway genes (Liquid Biopsy)
-
Detects: 15 Homologous Recombination Repair (HRR) pathway genes including BRCA1/2.
-
TAT: 14 working days
-
Test Code: MGM2455
Germline HRR (Homologous Recombination Repair) pathway genes analysis
-
Detects: 15 Homologous Recombination Repair (HRR) pathway genes including BRCA1/2.
-
TAT: 14 working days
-
Test Code: MGM1881
Tumour HRR (Homologous Recombination Repair) pathway genes analysis
-
Detects: 15 Homologous Recombination Repair (HRR) pathway genes including BRCA1/2.
-
TAT: 14 working days
-
Test Code: MGM1623
Key Highlights of MedGenome's HRR Track Test
Comprehensive HRR Gene Analysis
Detects mutations in 15 Homologous Recombination Repair (HRR) pathway genes, including BRCA1, BRCA2.
Indications
Prostate, Ovarian, Breast and Pancreatic Cancers.
High Analytical Sensitivity & Specificity
Achieves ≥95% sensitivity and 100% specificity for SNVs and InDels, ensuring accurate variant detection.
Get Genetic Counselling by Our Experts
Connect with Our Experts
MedGenome Patient Stories
MedGenome in the News
Explore Videos
Please share your details to get
in touch with our experts.
